US NIH stops ACTIV-2 phase 3 trial of Covid-19 drug candidate SAB-185
SAB Biotherapeutics said that the US National Institutes of Health (NIH) is discontinuing the phase 3 ACTIV-2 trial of the company’s SAB-185 for the treatment of Covid-19 because of low hospitalization and death rates in the trial. The National Institutes of Health is therefore stopping enrollment in its Covid-19 phase 3 trial, said the US-based […]
